3286 results about "Diagnostic Reagent" patented technology

Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.

Disclosed is a novel delta -endotoxin, designated CryET29, that exhibits insecticidal activity against siphonapteran insects, including larvae of the cat flea (Ctenocephalides felis), as well as against colcopteran insects, including the southern corn rootworm (Diabrotica undecimpunctata), western corn rootworm (D. virgifera), Colorado potato beetle (Leptinotarsa decemlineata), Japanese beetle (Popillia japonica), and red flour beetle (Tribolium castaneur). Also disclosed are nucleic acid segments encoding CryET29, recombinant vectors, host cells, and transgenic plants comprising a cryET29 DNA segment. Methods for making and using the disclosed protein and nucleic acid segments are disclosed as well as assays and diagnostic kits for detecting cryET29 and CryET29 sequences in vivo and in vitro.

Materials and methods for studying and modulating the interaction of carbohydrate-containing moieties with other species are described, in particular, small particles, e.g. clusters of metal or semiconductor atoms, which can be employed as a substrate for immobilising a plurality of ligands comprising carbohydrate groups. These “nanoparticles” can then be used to study carbohydrate mediated interactions, e.g. with other carbohydrates or proteins, and as therapeutics and diagnostic reagents.

The present invention relates to methods for the diagnosis, evaluation, and treatment of mood disorders, particularly bipolar disorder. In particular, patient test samples are analyzed for the presence and amount of members of a panel of biallelic markers comprising one or more specific markers for bipolar treatment and one or more non-specific markers for bipolar treatment. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. Algorithms for determining proper treatment are disclosed. A diagnostic kit for a panel of said markers is disclosed. In various aspects, the invention provides methods for the early detection and differentiation of mood disorders or bipolar treatment. Methods for screening therapeutic compounds for mood disorders are disclosed. The invention (1) gives methods providing rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, thereby reducing the costs associated with incorrect diagnosis, and (2) provides methods for improved therapies.

The present invention relates to methods for the diagnosis and evaluation of cardiovascular illness, particularly stroke, myocardial and other cardiovascular damage damage, hypertension treatment. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for cardiovascular illness or hypertension treatment and one or more non-specific markers for cardiovascular illness or hypertension treatment. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. Algorithms for determining proper treatment are disclosed. A diagnostic kit for a panel of said markers is disclosed. In various aspects, the invention provides methods for the early detection and differentiation of cardiovascular illness or hypertension treatment. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

Materials and methods for making small magnetic particles, e.g. clusters of metal atoms, which can be employed as a substrate for immobilising a plurality of ligands. Also disclosed are uses of these magnetic nanoparticles as therapeutic and diagnostic reagents, and in the study of ligand-mediated interactions.

The invention discloses humanized single-domain antibodies for a novel coronavirus SARS-CoV-2 and an application of the humanized single-domain antibodies. The invention protects the single-domain antibodies described in any one of SEQ ID No.1 to SEQ ID No.5. Experimental results show that the single-domain antibodies provided by the invention have good affinity with receptor binding domain (RBD)antigens and have high neutralization activity on SARS-CoV-2 pseudovirus. The humanized single-domain antibodies have important scientific significance and application prospect for prevention and clinical treatment of the new coronavirus SARS-CoV-2 and for development of diagnostic reagents of the new coronavirus SARS-CoV-2.

The invention provides materials and methods for the administration of an effectively magnetic medication or diagnostic reagent, or for the removal, sequestration, or effective conversion to a non-deleterious condition of a deleterious substance such as a toxin (e.g., biological, chemical, or radiological compound or composition) in vivo by administering a biocompatible magnetic particle to an organism in need, e.g., by delivery to the bloodstream, with the organism optionally having an internal magnetizable stent or magnetizable seed. The materials and methods are useful in the diagnosis and treatment of a variety of acute and chronic diseases, disorders and conditions afflicting man and other organisms, as well as for the removal of a variety of deleterious substances, including toxins, with the optional aid of an external magnetic generator and an optional magnetic filtration device.

The present invention relates to a method for diagnosing and / or monitoring a bacterial or parasitic infection by detection and quantification of the transrenal nucleic acids, derived from bacterial pathogenic agents or from parasites, in urine. The detection method optionally includes the isolation and the purification of the nucleic acids from urine by methods known in the art including pairing with molecular probes that are specific for the pathogenic agents, PCR hybridization, PCR, nested PCR, SSCP, LCR, and SDA. Diagnostic kits based on these detection methods are also claimed.

There is provided a preparation comprising Bifidobacterium breve and a mixture of non-digestible carbohydrates for non- or partially breast-fed infants as well as the use thereof for the treatment or prevention of immune disorder in non- or partially breast-fed infants. Also provided herein are sequence primers and probe for the detection of Bifidobacterium species as well as diagnostic kit thereof.

In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.

In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.

Single-molecule selection methods are provided for identifying target-binding molecules from diverse sequence and shape libraries. Complexes and imprints of selected target-binding molecules are also provided. The subject selection methods are used to identify oligonucleotide and nonnucleotide molecules with desirable properties for use in pharmaceuticals, drug discovery, drug delivery, diagnostics, medical devices, cosmetics, agriculture, environmental remediation, smart materials, packaging, microelectronics and nanofabrication. Single oligonucleotide molecules with desirable binding properties are selected from diverse sequence libraries and identified by amplification and sequencing. Alternatively, selected oligonucleotide molecules are identified by sequencing without amplification. Nonnucleotide molecules with desirable properties are identified by single-molecule selection from libraries of conjugated molecules or nucleotide-encoded nonnucleotide molecules. Alternatively, target-specific nonnucleotide molecules are prepared by imprinting selected oligonucleotide molecules into nonnucleotide molecular media. Complexes and imprints of molecules identified by single-molecule selection are shown to have broad utility as drugs, prodrugs, drug delivery systems, willfully reversible cosmetics, diagnostic reagents, sensors, transducers, actuators, adhesives, adherents and novel multimolecular devices.

Devices are provided for medical diagnostics comprising a substrate; an array of reservoirs; one or more electrodes located at least partially inside the reservoirs; a plurality of discrete reservoir caps covering openings in the plurality reservoirs; control circuitry for selectively disintegrating or permeabilizing the reservoir cap over a reservoir opening; and, optionally, a diagnostic reagent in the reservoirs. Devices also are provided for the controlled delivery of molecules comprising a substrate; an array of reservoirs; a release system in the reservoirs comprising molecules for release; one or more electrodes attached to the substrate inside the reservoirs or to a surface outside of the reservoirs, wherein the electrodes are not reservoir caps; and means for applying an electric current or potential across the electrodes effective to activate release of the molecules from the reservoirs. The devices can be adapted for implantation for in vivo diagnostics or drug delivery.

The invention relates to kits and methods for aiding the diagnosis of Barrett's oesophagus or Barrett's associated dysplasia. Preferred is a method comprising assaying cells from the surface of a subject's oesophagus for a non-squamous cellular marker, wherein detection of such a marker indicates increased likelihood of the presence of Barrett's or Barrett's associated dysplasia, preferably wherein said sample of cells is not directed to a particular site within the oesophagus. The invention also encompasses a method comprising sampling the cellular surface of the oesophagus of said subject. The invention also relates to a kit comprising a swallowable device comprising abrasive material capable of collecting cells from the surface of the oesophagus, together with printed instructions for its use in detection of Barrett's oesophagus or Barrett's associated dysplasia. Preferably said device comprises a capsule sponge.

Mutant BNIP3 plays a functionally important role in the development of solid tumors and in resistance to chemotherapy and radiation treatments. The invention relates to methods of detecting cancer, methods of monitoring the progression of cancer, methods of identifying patients with cancer that is resistant to chemotherapy or radiation treatments, and diagnostic kits for performing the methods of the invention.

The invention relates to a neutralizing antibody for resisting a novel coronavirus SARS-Cov-2 and an application of the neutralizing antibody. The antibody at least comprises one of a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3. The antibody can be used for preparing a diagnostic reagent or a diagnostic kit, a drug or a pharmaceutical composition for detecting, preventing and treating a COVID-19. According to the neutralizing antibody, differential antibody screening is carried out through a phage display technology ina manner of targeting SARS-Cov-2-RBD and SARS-Cov-1-RBD; the neutralizing antibody for resisting the novel coronavirus SARS-Cov-2 is obtained; binding of the SARS-Cov-2-RBD and ACE2 positive cells can be blocked; and the neutralizing antibody has a remarkable virus neutralizing effect on an SARS-Cov-2 pseudo virus and provides an effective alternative antibody drug for prevention and treatment ofthe COVID-19.

Disclosed are compositions and methods for isolating, detecting, amplifying, and quantitating Mycobacterium-specific nucleic acids in a sample. Also disclosed are compositions and diagnostic kits comprising Mycobacterium IS6110-specific oligonucleotide amplification primers and labeled oligonucleotide detection probes that specifically bind to the amplification products obtained therefrom. Also disclosed are compositions and methods for the isolation and characterization of nucleic acids that are specific to one or more tubercular pathogens, including Mycobacterium tuberculosis, in particular, from a wide variety of samples including those of biological, environmental, clinical and / or veterinary origin.

CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.

CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.

Tri- and tetra substituted thiepane compositions having use as immunogens, therapeutics, diagnostics and for other industrial purposes are disclosed. The compositions inhibit proteolytic activity of viral enzymes and are useful for the inhibition of such enzymes as well as in assays for the detection of such enzymes. Embodiments in which antigenic polypeptides are bonded to the compositions are useful in raising antibodies against the thiepane haptens or the polypeptide. Labeled thiepanes of this invention are useful as diagnostic reagents.

The present invention relates generally to groups of genes that can be used to diagnose and differentiate between types of specific diseases such as breast cancer. The groups of genes can be further used to develop diagnostic kits for the specific diseases. The diagnostic kits can also differentiate between sub-categories of a disease to help identify the appropriate treatment regimen for a patient.

A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and / or treating interstitial cystitis and cancer are disclosed.

The invention discloses a method for establishing a fragile X-syndrome non-human primate model on the basis of a CRISPR gene knockout technology. The method comprises the following steps: (1) establishing a FMR1 gene knockout machin model; (2) carrying out identification and related functional analysis on the machin model; (3) carrying out tests on the nerve characteristics and learning and memorizing ability of the machin model. The method utilizes a CRISPR gene knockout technology to establish a fragile X-syndrome non-human primate model. The model fills the blank of non-human primate model, can effectively stimulate the pathological process of human diseases, can be used as an optimum animal model for researching human diseases, can effectively predict the effect of novel vaccine, novel drug or novel diagnostic reagent in clinical applications, and thus greatly reduces the risk of novel drug development.

invention discloses a kit for a serum micro-ribonucleic acid and the application in the early diagnosing of hepatitis B thereof which belong to the technical field of biotechnological pharmaceutics. The invention provides the combination of the micro-ribonucleic acid used for estimating the physiological and / or pathological states of a normal person, a HBVer and a patient with hepatitis B; the combination comprises all the micro-ribonucleic acids which have differential expression in the serum / plasm of the normal person, the HBVer and the patient with hepatitis B and prepares a diagnosing kit which can be used for the early diagnosing of hepatitis B. The combination and the method can be used for the early detection and nondirective therapy of hepatitis B; besides, the combination and the method have the advantages of high specificity, high efficiency, high sensitivity, low detection cost, convenient material obtaining, and the like. Besides, the samples are easily stored.

The invention discloses a nucleic acid amplification system and a freeze-drying protective agent thereof. The nucleic acid amplification system comprises a buffer solution, an enzyme mixing solution, a nucleic acid amplification reaction solution and the low-temperature freeze-drying protective agent. The buffer solution further comprises one or more of dNTP, Mgcl2, Thris-Hcl and KCl. The enzyme mixing solution further comprises one or more of RNA reverse transcriptase, RAN inhibitor and DNA polymerase. A preparation method for the freeze-drying protective agent applied to the nucleic acid amplification system comprises the following step that the components are mixed to be uniform according to the adopted concentration ratio to obtain the freeze-drying protective agent. An RNA / DNA fluorescent quantitation nucleic acid diagnostic reagent system can be detected in a freeze-drying mode, freeze drying can be achieved, the detection purpose can be achieved only through one-step hydration, and the purposes of normal temperature transportation and storage which cannot be achieved by a nucleic acid diagnostic reagent at the present stage can be achieved.

The present invention relates generally to a novel haemopoietin receptor or components or part thereof and to genetic sequences encoding same. The receptor molecules and their components and / or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.

The present invention relates to a method for diagnosing and / or monitoring a bacterial or parasitic infection by detection and quantification of the transrenal nucleic acids, derived from bacterial pathogenic agents or from parasites, in urine. The detection method optionally includes the isolation and the purification of the nucleic acids from urine by methods known in the art including pairing with molecular probes that are specific for the pathogenic agents, PCR hybridization, PCR, nested PCR, SSCP, LCR, and SDA. Diagnostic kits based on these detection methods are also claimed.

The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV. The present invention also provides a rapid, sensitive, and consistent method for the specific detection of DENV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-DENV antibodies but do not cross-react with antibodies against other flaviviruses such as JEV, SLEV, or WNV. Further, the DENV NS5 antigens are serospecific and do not cross react with antibodies to other DENV strains. Thus, the method of the present invention provides a manner by which to discriminate infections by each DENV strain. Further, diagnostic kits for carrying out the methods are provided. The methods and kits for carrying out the methods of the invention are rapid and require as little as 10 minutes to detect a result.